Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 3/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14996220 | 1.00 | ZDHHC2 (0.50) | ZDHHC2MGLLNAAAEPHX1ALDH1A1 | |
| SCHEMBL13630803 | 0.99 | ZDHHC2 (0.52) | ZDHHC2MGLLNAAAEPHX1ALDH1A1 | |
| SCHEMBL13617146 | 0.90 | MAPT (0.40) | ZDHHC2MGLLALDH1A1 | |
| SCHEMBL13617147 | 0.85 | ZDHHC2 (0.36) | ZDHHC2MGLL | |
| SCHEMBL14996210 | 0.85 | HPGD (0.40) | ZDHHC2MGLLALDH1A1HTT | |
| SCHEMBL24654022 | 0.84 | KMT2A (0.38) | ZDHHC2MGLL | |
| SCHEMBL21597554 | 0.84 | KMT2A (0.41) | ZDHHC2MGLLALDH1A1 | |
| SCHEMBL21597555 | 0.84 | KMT2A (0.41) | ZDHHC2MGLLALDH1A1 | |
| SCHEMBL13066415 | 0.84 | KMT2A (0.41) | ZDHHC2MGLLALDH1A1 | |
| SCHEMBL29306423 | 0.84 | SMN1; SMN2 (0.46) | ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3252045-B1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | ABBVIE INC (US) | 2019-09-04 | — | — | EP | disclosed |
| US-10112911-B2 | Substituted cyanoguanidines as oral anti-virals | ABBVIE INC. (US) | 2018-10-30 | — | — | US | disclosed |
| EP-2867221-B1 | CYANOGUANIDINES AND THEIR SUE AS ANTIVIRAL AGENTS. | ABBVIE INC (US) | 2018-01-17 | — | — | EP | disclosed |
| EP-3252045-A1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | AbbVie Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20150322045-A1 | CYANOGUANIDINES AND USES THEREOF | ABBVIE INC. | 2015-11-12 | — | — | US | disclosed |
| EP-2867221-A1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | AbbVie Inc. (US) | 2015-05-06 | — | — | EP | disclosed |
| WO-2014005129-A1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | ABBVIE INC. (US) | 2014-01-03 | — | — | WO | disclosed |
| EP-1791830-B1 | DIAMINOTRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7329652-B2 | Diaminotriazole compounds useful as protein kinase inhibitors | VERTEX PHARAMACEUTICALS INCORPORATED (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1791830-A1 | DIAMINOTRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006034116-A1 | DIAMINOTRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063756-A1 | Diaminotriazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322045-A1 | CYANOGUANIDINES AND USES THEREOF | GMPS, RNGTT, RNMT | ZDHHC2 4719/4885MGLL 3991/4885NAAA 1113/4885 |
| US-20060063756-A1 | Diaminotriazole compounds useful as protein kinase inhibitors | JAK2, JAK3, JAK1 | ZDHHC2 2547/4885MGLL 4545/4885NAAA 3085/4885 |
| US-10112911-B2 | Substituted cyanoguanidines as oral anti-virals | RNGTT, GMPS, RNMT | ZDHHC2 4857/4885MGLL 4262/4885NAAA 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.